Cargando…
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
BACKGROUND: Adjuvant immune checkpoint blockade (ICB) following chemoradiotherapy and adding ICB to chemotherapy have been key advances for stages III-IV non-small cell lung cancer (NSCLC) treatment. However, known biomarkers like PD-L1 are not consistently indicative of ICB response. Other markers...
Autores principales: | Gao, Yinjie, Stein, Michelle M., Kase, Matthew, Cummings, Amy L., Bharanikumar, Ramit, Lau, Denise, Garon, Edward B., Patel, Sandip P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870967/ https://www.ncbi.nlm.nih.gov/pubmed/35881197 http://dx.doi.org/10.1007/s00262-022-03252-y |
Ejemplares similares
-
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
por: Cummings, Amy L., et al.
Publicado: (2017) -
PromoterPredict: sequence-based modelling of Escherichia coli σ(70) promoter strength yields logarithmic dependence between promoter strength and sequence
por: Bharanikumar, Ramit, et al.
Publicado: (2018) -
Riboflow: Using Deep Learning to Classify Riboswitches With ∼99% Accuracy
por: Premkumar, Keshav Aditya R., et al.
Publicado: (2020) -
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020) -
Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
por: Heij, Lara, et al.
Publicado: (2023)